Boehringer Ingelheim has opened a site in Shanghai to connect its R&D, business development and venture capital groups to Chinese drug developers. The site brings together all the units involved in the identification and support of promising drug development projects.
With China’s domestic biotech scene blossoming, Boehringer has identified the country as a source of programs of interest to its business development and venture funding groups. That thinking led Boehringer to choose Shanghai as the location for an External Innovation Hub designed to connect the company to the Chinese life science sector..